Physician profile
Marco Ghignone
NPI 1366422172
$1,642.56
in general payments reported to CMS, 2019-2025
13 companies · $345 in 2025
The $345 reported for 2025 was less than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $113 · 2020: $138 · 2021: $85.13 · 2022: $174 · 2023: $233 · 2024: $554 · 2025: $345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,132.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $394.04 | 2019-2022 | |
| Medtronic, INC. | $358.73 | 2024-2025 | Intellis Adaptivestim, Synchromedii, Inceptiv |
| Spr Therapeutics, INC | $219.12 | 2023-2025 | Sprint Pns System |
| Saluda Medical Americas, INC. | $164.14 | 2024 | Evoke |
| Spinal Simplicity, LLC | $133.15 | 2024-2025 | Ha Minuteman G3-R |
| Relievant Medsystems, INC. | $118.64 | 2023 | Intracept |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $100.58 | 2019-2024 | Relistor |
| Boston Scientific Corporation | $71.79 | 2023-2025 | Superion Indirect Decompression System, Intracept |
| Kowa Pharmaceuticals America, INC. | $18.84 | 2022 | |
| Redhill Biopharma INC. | $18.27 | 2021 | |
| Bioventus LLC | $16.90 | 2019 | |
| Sentynl Therapeutics, INC. | $14.59 | 2019 | |
| Hikma Pharmaceuticals USA | $13.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marco Ghignone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.